Latest / The Well-Built Life / Treating Depression with Thyroid Hormone and Psychedelics
Transcript
- 0:00Speaker 1: Hey, everyone, welcome back to the well Built Life. I
- 0:03Speaker 1: am really glad you are here today. This is a
- 0:05Speaker 1: space where we cut through the complicated trends and confusing
- 0:08Speaker 1: advice to talk about what actually works for your health, fitness,
- 0:12Speaker 1: and overall well being. No intense jargon, no extreme rules,
- 0:16Speaker 1: just simple practical tips you can easily fit into your
- 0:20Speaker 1: everyday routine to feel a little stronger, healthier, and more balanced.
- 0:26Speaker 1: Grab a drink, get comfortable, and let us dive into
- 0:29Speaker 1: today's conversation. In treating a patient with severe anxiety and
- 0:33Speaker 1: racing heart, I considered the possibility of elevated TSH and
- 0:38Speaker 1: free T four, which pointed towards hyperthyroidism. Symptoms like palpitations,
- 0:44Speaker 1: high heart rate, and sweating were more typical in this condition,
- 0:48Speaker 1: often managed by an endocrinologist. However, less severe cases can
- 0:52Speaker 1: present with anxiety, including palpitations and insomnia. Hyperthyroidism is more
- 0:59Speaker 1: common in psychiatric patients and would typically need T four treatment,
- 1:03Speaker 1: but for more precise dosing, a combination of T four
- 1:06Speaker 1: and T three is often preferred. While labs are helpful,
- 1:10Speaker 1: the primary focus in these scenarios is symptom management. When
- 1:14Speaker 1: discussing T three, therapy for treatment resistant depression. I often
- 1:19Speaker 1: recommend starting with a regimen of two point five micrograms
- 1:22Speaker 1: twice a day, usually around six to eight hrs apart
- 1:26Speaker 1: to avoid late night dose timing that can induce insomnia.
- 1:30Speaker 1: The maximum dose can be as high as twenty five
- 1:32Speaker 1: micrograms twice a day for severely depressed patients who maintain
- 1:36Speaker 1: a normal blood pressure and pulse. Case studies often highlight
- 1:41Speaker 1: the use of T three as a last resort augmentation
- 1:44Speaker 1: strategy when other treatments have failed. When tapering off medications,
- 1:49Speaker 1: it's crucial to prioritize the efficacy of the treatment, which
- 1:52Speaker 1: means maintaining minimal T three therapy while eventually considering the
- 1:56Speaker 1: removal of other drugs. High dose of T three carry
- 2:01Speaker 1: significant risks and side effects, as they can be detrimental
- 2:04Speaker 1: to the patient's overall health. Patients might not present with
- 2:08Speaker 1: dramatic thyroid lab results responding to thyroid hormone supplementation in
- 2:13Speaker 1: depressed patients with low normal free T four or T
- 2:17Speaker 1: three levels suggests effects beyond simple hormone replacement. The upregulation
- 2:22Speaker 1: of metabolism and increased metabolic rate are considered primary mechanisms
- 2:27Speaker 1: for the response to thyroid hormone supplementation, which can increase
- 2:32Speaker 1: cocolamine receptor response and elevate nourepinephrine and dopamine levels. Mitochondrial
- 2:38Speaker 1: biogenesis is also enhanced, contributing to the overall response. There
- 2:43Speaker 1: are four primary hormonal axes thyroid, androgen, adrenal, cortical and
- 2:48Speaker 1: fuel partitioning that can be involved the cortisol pathway. Managing
- 2:53Speaker 1: the HPA axis often presents as a challenging area, as
- 2:58Speaker 1: hyper arousal is a common ise in psychiatric conditions but
- 3:02Speaker 1: lacks a straightforward treatment. Treatment usually involves a collaborative, interdisciplinary approach,
- 3:08Speaker 1: and sometimes simplified language is needed to address patients, such
- 3:12Speaker 1: as suggesting they ask for a job transfer or higher help.
- 3:16Speaker 1: The concept of psychic pharmaco logic is important, indicating a
- 3:20Speaker 1: holistic approach to prescription. In a case of recalcitrant depression,
- 3:25Speaker 1: a high dose of T three was used, which proved
- 3:27Speaker 1: to be the key to recovery. However, in diagnosing a
- 3:31Speaker 1: patient experiencing overwhelming emotions and thoughts, menopause was a crucial
- 3:36Speaker 1: clue indicating an underlying diagnosis of bipolar disorder. Treatment with
- 3:41Speaker 1: lamotrigine led to an organizing hypothesis which ultimately clarified the
- 3:46Speaker 1: patient's long standing difficulties and provided hope for future improvement.
- 3:51Speaker 1: When a patient had a past history of bipolar depression
- 3:55Speaker 1: with a hypomanic period followed by a depressive episode and
- 3:59Speaker 1: inability to fireunction, stopping a medication due to severe racing
- 4:03Speaker 1: thoughts and insomnia return the patient to their initial hypomanic symptoms.
- 4:08Speaker 1: Despite the complexity at the molecular level, the speaker suspects
- 4:11Speaker 1: limbic dysregulation psychiatry faces challenges in understanding such intricate processes,
- 4:17Speaker 1: and ketamine, an NMDA receptor antagonist, has seen increasing interest.
- 4:22Speaker 1: Ketamine blocks GABA inter neurons, releasing glutamate and inducing rapid neuroplasticity,
- 4:28Speaker 1: and can significantly reduce suicidal risk in severely depressed patients. However,
- 4:34Speaker 1: it is often used as a temporary solution with other
- 4:37Speaker 1: treatments required for long term relief, and its effectiveness can
- 4:41Speaker 1: diminish over time. The speaker notes that the administration of
- 4:45Speaker 1: ketamine involves intravenous infusions with monitoring, and some might undergo
- 4:50Speaker 1: treatments three or more times weekly. Relief duration can last days,
- 4:54Speaker 1: and long term effects are unpredictable, making it difficult to
- 4:58Speaker 1: determine true efficacy. Let's shift gears a bit. I spoke
- 5:02Speaker 1: earlier about hyperausal and the thyroid and its axis, but
- 5:07Speaker 1: it's crucial to note that thyroid hormone supplementation isn't always
- 5:11Speaker 1: the cure all. For instance, there is a patient I
- 5:14Speaker 1: had whom we tried to balance with various medications, but
- 5:18Speaker 1: the T the third of August menation strategy emerged as
- 5:22Speaker 1: the last ditch effort. This patient had unipolar depression and
- 5:26Speaker 1: despite multiple trials with SSRIs and even well buttrin lithium
- 5:31Speaker 1: and atypical antipsychotics, there was minimal improvement. Then we decided
- 5:37Speaker 1: to try a high dose of T three, starting with
- 5:39Speaker 1: two point five micrograms twice a day. We aim to
- 5:43Speaker 1: slowly titrate this to the maximum needed. The patient's response
- 5:47Speaker 1: was transformative. Essentially, it was the unlocking key to their recovery.
- 5:51Speaker 1: But along the way I explained to them why we
- 5:54Speaker 1: were using estrogen and thyroid medications, not hyperourzol directly. The
- 5:59Speaker 1: goal was to manage metabolic and hormonal processes that underpin
- 6:03Speaker 1: mood and cognitive function, rather than treating the symptoms directly.
- 6:08Speaker 1: Hyper arousal, as I mentioned, is a maladaptive stress response,
- 6:12Speaker 1: often due to caregiving burdens, work overload, or medical illnesses.
- 6:16Speaker 1: We always emphasize that patients should take steps to manage
- 6:19Speaker 1: these stressors, but the reality is we can often treat
- 6:23Speaker 1: the symptoms more effectively than the underlying causes. Another interesting
- 6:28Speaker 1: case involved a patient who presented with severe menopausal symptoms
- 6:33Speaker 1: that led to a misdiagnosis of bipolar disorder. Initially, we
- 6:36Speaker 1: thought the overwhelming emotions and racing thoughts were a byproduct
- 6:40Speaker 1: of menopause, but as we delved deeper, we realized her
- 6:43Speaker 1: hypomanic episodes followed a distinct pattern intense productivity followed by
- 6:48Speaker 1: depressive episodes and a total inability to function. This suggested
- 6:53Speaker 1: a broader spectrum disorder. Even though the initial evidence pointed
- 6:57Speaker 1: towards a straightforward mood fluctuation, Her treatment lamotrogene provided and
- 7:03Speaker 1: organizing hypothesis. It clarified the patient's long standing difficulties and
- 7:08Speaker 1: started her on a path towards managing the bipolar depression.
- 7:11Speaker 1: The hope is always there, but the reality is many
- 7:14Speaker 1: factors contribute to these conditions and treating them requires a nuanced,
- 7:18Speaker 1: multifaceted approach. Moving on to a more controversial topic, I
- 7:23Speaker 1: mention ketamine, an n m DA receptor antagonist. It's intriguing
- 7:27Speaker 1: because it's been a game changer for many severely depressed patients,
- 7:32Speaker 1: but the mechanisms are still not fully understood. Limbic dysregulation
- 7:36Speaker 1: is suspected, but the exact molecular processes remain elusive. The
- 7:41Speaker 1: complexity of understanding these molecular mechanisms in the brain continues
- 7:45Speaker 1: to challenge us. Ketamine's use is often seen as a
- 7:49Speaker 1: temporary solution, complementing other more traditional treatments. Its effectiveness can
- 7:54Speaker 1: diminish over time, but it remains a powerful tool for
- 7:58Speaker 1: acute symptom relief. I have treated two dozen patients, with
- 8:02Speaker 1: some seeing immediate relief, but also some who need frequent
- 8:06Speaker 1: infusions due to the unpredictable nature of the drugs effects.
- 8:09Speaker 1: The administration involves intravenous infusions that require careful monitoring, increasing
- 8:16Speaker 1: the treatment's time and cost. Still, for some it's a lifeline. Lastly,
- 8:22Speaker 1: I shared a case involving the use of psilocybin a
- 8:26Speaker 1: Japanese woman with a ten year diagnosis of severe Alzheimer's
- 8:30Speaker 1: experienced dramatic improvement, but the case is ambiguous and the
- 8:34Speaker 1: end of one is clearly insufficient for any definitive conclusions. However,
- 8:39Speaker 1: it sparked further interest in the potential of psychedelics for
- 8:42Speaker 1: neuroplasticity and treating conditions like PTSD and depression. The Rebus
- 8:47Speaker 1: model proposed by Robin Carhart Harris suggests that psychedelics can
- 8:52Speaker 1: relax cognitive set, allowing for rewirable neural pathways. This opens
- 8:57Speaker 1: up a therapeutic window that can be incredible, transformative, yet unpredictable.
- 9:03Speaker 1: The limitations in diagnosis and treatment, especially for severe conditions
- 9:08Speaker 1: like Alzheimer's, highlight the need for more research. We are
- 9:12Speaker 1: cautiously optimistic, but wary due to the potential risks and
- 9:16Speaker 1: the lack of a definitive set and setting or dose
- 9:19Speaker 1: that would guarantee success. The idea of using psychedelics and
- 9:23Speaker 1: psychiatry remains a frontier, fraught with challenges, but full of promise. Certainly,
- 9:29Speaker 1: here is the monolog for section three. Let's dive into
- 9:33Speaker 1: the use of t the third of august mentation in
- 9:35Speaker 1: treatment resistant depression. The concept here is to exploit the
- 9:40Speaker 1: physiological and psychological effects of a heightened metabolic state. Initially,
- 9:46Speaker 1: we present the case of a patient whose depression had
- 9:48Speaker 1: responded minimally to various monotherapies and combination treatments. After multiple
- 9:54Speaker 1: unsuccessful attempts, we initiated a trial with levithyroxine T three.
- 10:00Speaker 1: The patient's experience was profound. She reported increased energy levels,
- 10:05Speaker 1: improved concentration, and a general feeling of well being that
- 10:09Speaker 1: had been absent for years. Importantly, these effects were noticed
- 10:13Speaker 1: even with the minimal dosing of two point five micrograms
- 10:16Speaker 1: twice a day. Emphasizing the efficacy of T the third
- 10:20Speaker 1: of August menation. To manage the side effects, which could
- 10:23Speaker 1: include anxiety and insomnia, we titrated the dose slowly and
- 10:28Speaker 1: monitored the patient closely. She experienced some initial restlessness, but
- 10:33Speaker 1: adjustments to her dosing schedule and the addition of short
- 10:36Speaker 1: acting T three sidyl cypraterone helped mitigate these issues. We
- 10:41Speaker 1: aimed to maintain a balance between therapeutic effects and patient
- 10:44Speaker 1: quality of life. The T three regimen was part of
- 10:48Speaker 1: a broader strategy that included psychotherapy and lifestyle changes. We
- 10:53Speaker 1: emphasized the importance of a holistic approach, recognizing that depression
- 10:57Speaker 1: is a complex interplay of biological, psychological, and social factors.
- 11:02Speaker 1: The patient's response to T three also highlighted the need
- 11:06Speaker 1: for a flexible and adaptive treatment plan. While T the
- 11:09Speaker 1: third of August mentation was effective, it's crucial to remember
- 11:13Speaker 1: the potential risks. Prolonged use of high dose T three
- 11:17Speaker 1: can lead to significant adverse effects such as tachycardia, hyperthyroid symptoms,
- 11:23Speaker 1: and cardiac issues. Therefore, we recommend monitoring thyroid function tests
- 11:28Speaker 1: regularly and adjusting the dose based on clinical need. In summary,
- 11:34Speaker 1: T the third of August mentation can be a valuable
- 11:37Speaker 1: tool in the treatment of severe depression when other options fail. However,
- 11:42Speaker 1: it should be used with caution under careful medical supervision
- 11:46Speaker 1: to ensure both efficacy and safety. This monologue encapsulates the
- 11:51Speaker 1: key points and provides a balanced view of the potential
- 11:55Speaker 1: and risks associated with T the third of August mentation.
- 12:00Speaker 1: Inhibition of the five HT two A receptor plays a
- 12:04Speaker 1: critical role in the efficacy of psychedelic substances, making it
- 12:08Speaker 1: a potential target for pharmacological strategies. By modulating this receptor,
- 12:13Speaker 1: we can augment the therapeutic benefits while mitigating potential risks.
- 12:18Speaker 1: Both MDMA and psilocybin are showing promise in specific psychiatric conditions,
- 12:24Speaker 1: particularly MDMA in treating PTSD and psilocybin for end of
- 12:28Speaker 1: life depression. PTSD treatment presents unique challenges due to the
- 12:33Speaker 1: heterogeneity of its manifestations. Despite these challenges, evidence suggests that
- 12:38Speaker 1: MDMA may have a specific role in enhancing empathy, which
- 12:41Speaker 1: can be crucial in trauma recovery. However, every treatment approach
- 12:46Speaker 1: must be highly individualized, as what works for one patient
- 12:49Speaker 1: may not work for another due to the complex and
- 12:52Speaker 1: varied nature of PTSD symptoms. Psilocybin, on the other hand,
- 12:56Speaker 1: is being considered for its potential in end of life depression,
- 13:01Speaker 1: where the risk benefit ratio is more favorable. The medical
- 13:06Speaker 1: community is facing the delicate balance of providing powerful and
- 13:10Speaker 1: positive treatments while being cautious about the risks. Despite the
- 13:14Speaker 1: limited awareness of adverse stories compared to positive ones, every drug,
- 13:19Speaker 1: including those prescribed by doctors, has potential side effects. Thus,
- 13:24Speaker 1: careful consideration and individualized care are paramount in delivering effective
- 13:29Speaker 1: and safe psychiatric treatments. That brings us to the end
- 13:34Speaker 1: of today's episode. Thank you so much for spending part
- 13:37Speaker 1: of your day with me. If you found this episode's
- 13:40Speaker 1: tips helpful and want to make sure you don't miss
- 13:42Speaker 1: the next conversation, please take a quick second to hit
- 13:45Speaker 1: that subscribe or follow button on whatever platform you are
- 13:48Speaker 1: listening on. It's a completely free way to support the
- 13:51Speaker 1: show and helps more people find us. This podcast is
- 13:55Speaker 1: independently produced, so if you are ever in a position
- 13:58Speaker 1: where you would like to help keep it running, we
- 14:00Speaker 1: do accept small dogations. You can find a link right
- 14:03Speaker 1: in the episode description below to buy us a coffee
- 14:05Speaker 1: or contribute what you can. Every bit genuinely helps take
- 14:10Speaker 1: care of yourself, stay balanced, and we will talk again soon.